Ticker Symbol: GERN
Geron Corp.
$1.51 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0000886744
Company Profile
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 919 East Hillsdale Boulevard
Website: www.geron.com
CEO: John Scarlett
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $1.87
Change:
-$0.12
(
-6.03%)
Days Range: $1.85 - $2.00
Beta: 1.24
52wk. High: $3.84
52wk. Low: $1.73
Ytd. Change -23.80%
50 Day Moving Average: $2.06
200 Day Moving Average: $2.69
Shares Outstanding: 523370675
Valuation
Market Cap: 97.9B
PE Ratio: -5.14
EPS (TTM): -0.3641
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A